Logo image of BNOX

BIONOMICS LTD-ADR (BNOX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BNOX - US09063M2052 - ADR

0.2531 USD
+0.01 (+4.2%)
Last: 12/23/2024, 8:00:01 PM
0.4002 USD
+0.15 (+58.12%)
After Hours: 12/23/2024, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, BNOX scores 2 out of 10 in our fundamental rating. BNOX was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of BNOX have multiple concerns. BNOX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BNOX had negative earnings in the past year.
In the past 5 years BNOX always reported negative net income.
BNOX had a negative operating cash flow in each of the past 5 years.
BNOX Yearly Net Income VS EBIT VS OCF VS FCFBNOX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

BNOX's Return On Assets of -131.15% is on the low side compared to the rest of the industry. BNOX is outperformed by 82.94% of its industry peers.
BNOX's Return On Equity of -175.51% is on the low side compared to the rest of the industry. BNOX is outperformed by 66.79% of its industry peers.
Industry RankSector Rank
ROA -131.15%
ROE -175.51%
ROIC N/A
ROA(3y)-41.13%
ROA(5y)-32.67%
ROE(3y)-50.86%
ROE(5y)-54.3%
ROIC(3y)N/A
ROIC(5y)N/A
BNOX Yearly ROA, ROE, ROICBNOX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BNOX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BNOX Yearly Profit, Operating, Gross MarginsBNOX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50K -100K

More info and screens

3

2. Health

2.1 Basic Checks

BNOX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNOX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BNOX Yearly Shares OutstandingBNOX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
BNOX Yearly Total Debt VS Total AssetsBNOX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -11.22, we must say that BNOX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -11.22, BNOX is doing worse than 77.38% of the companies in the same industry.
BNOX has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BNOX (0.05) is worse than 61.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -11.22
ROIC/WACCN/A
WACC10.42%
BNOX Yearly LT Debt VS Equity VS FCFBNOX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

BNOX has a Current Ratio of 3.81. This indicates that BNOX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BNOX (3.81) is comparable to the rest of the industry.
BNOX has a Quick Ratio of 3.81. This indicates that BNOX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.81, BNOX perfoms like the industry average, outperforming 46.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.81
Quick Ratio 3.81
BNOX Yearly Current Assets VS Current LiabilitesBNOX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for BNOX have decreased strongly by -115.72% in the last year.
BNOX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.62%.
The Revenue for BNOX have been decreasing by -64.58% on average. This is quite bad
EPS 1Y (TTM)-115.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-86.62%
Revenue growth 3Y-8.9%
Revenue growth 5Y-64.58%
Sales Q2Q%N/A

3.2 Future

BNOX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.76% yearly.
BNOX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 118.41% yearly.
EPS Next Y33.83%
EPS Next 2Y28.37%
EPS Next 3Y-16.76%
EPS Next 5YN/A
Revenue Next Year-80.75%
Revenue Next 2Y-45.51%
Revenue Next 3Y118.41%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BNOX Yearly Revenue VS EstimatesBNOX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 20M 40M 60M
BNOX Yearly EPS VS EstimatesBNOX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNOX. In the last year negative earnings were reported.
Also next year BNOX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNOX Price Earnings VS Forward Price EarningsBNOX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNOX Per share dataBNOX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as BNOX's earnings are expected to decrease with -16.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.37%
EPS Next 3Y-16.76%

More info and screens

0

5. Dividend

5.1 Amount

BNOX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONOMICS LTD-ADR

NASDAQ:BNOX (12/23/2024, 8:00:01 PM)

After market: 0.4002 +0.15 (+58.12%)

0.2531

+0.01 (+4.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-21 2024-02-21
Earnings (Next)N/A N/A
Inst Owners16.93%
Inst Owner Change-78.02%
Ins Owners38.23%
Ins Owner Change0%
Market Cap4.94M
Revenue(TTM)22.05K
Net Income(TTM)-31.85M
Analysts82.5
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)37.77%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-34.81%
Revenue NY rev (3m)-34.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 224.14
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 1.04
EV/EBITDA N/A
EPS(TTM)-3.12
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.93
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -131.15%
ROE -175.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.13%
ROA(5y)-32.67%
ROE(3y)-50.86%
ROE(5y)-54.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.81
Quick Ratio 3.81
Altman-Z -11.22
F-ScoreN/A
WACC10.42%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-115.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y33.83%
EPS Next 2Y28.37%
EPS Next 3Y-16.76%
EPS Next 5YN/A
Revenue 1Y (TTM)-86.62%
Revenue growth 3Y-8.9%
Revenue growth 5Y-64.58%
Sales Q2Q%N/A
Revenue Next Year-80.75%
Revenue Next 2Y-45.51%
Revenue Next 3Y118.41%
Revenue Next 5YN/A
EBIT growth 1Y-136.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.65%
OCF growth 3YN/A
OCF growth 5YN/A

BIONOMICS LTD-ADR / BNOX FAQ

Can you provide the ChartMill fundamental rating for BIONOMICS LTD-ADR?

ChartMill assigns a fundamental rating of 2 / 10 to BNOX.


Can you provide the valuation status for BIONOMICS LTD-ADR?

ChartMill assigns a valuation rating of 0 / 10 to BIONOMICS LTD-ADR (BNOX). This can be considered as Overvalued.


How profitable is BIONOMICS LTD-ADR (BNOX) stock?

BIONOMICS LTD-ADR (BNOX) has a profitability rating of 0 / 10.